Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Cevostamab + Tocilizumab |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Cevostamab | RO7187797|BFCR4350A | CD3 Antibody 86 | Cevostamab (BFCR4350A) is a bispecific antibody that targets both FCRH5 and CD3, potentially resulting in increased anti-tumor immune response and tumor cell killing (Blood (2020) 136 (Supplement 1): 42-43). | |
Tocilizumab | Actemra | Atlizumab | Actemra (tocilizumab) is a humamized monoclonal antibody that targets IL-6R, resulting in decreased downstream signaling and potentially resulted in decreased tumor growth and progression (PMID: 26751841, PMID: 25658637). Actemra (tocilizumab) is FDA approved for use in treating rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, and systemic juvenile idiopathic arthritis (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04910568 | Phase I | Cevostamab + Tocilizumab | A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma | Recruiting | USA | ITA | FRA | ESP | CAN | AUS | 5 |
NCT05535244 | Phase Ib/II | Cevostamab + Tocilizumab | A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myeloma (CAMMA 2) | Recruiting | USA | ITA | ESP | DEU | BEL | AUS | 1 |
NCT05646836 | Phase I | Cevostamab + Tocilizumab Cevostamab + RO7310729 + Tocilizumab | A Study to Evaluate the Safety, Pharmacokinetics, and Activity of XmAb24306 in Combination With Cevostamab in Participants With Relapsed/Refractory Multiple Myeloma | Recruiting | ESP | AUS | 4 |